Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
25. Juni 2024 16:30 ET
|
Cingulate Inc.
KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
21. Mai 2024 09:00 ET
|
Cingulate Inc.
Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application
Advancing Discussions with Commercialization Partners
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
13. November 2023 16:15 ET
|
Cingulate Inc.
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE...
Cingulate to Host CNS Key Opinion Leader Panel in New York City
17. Oktober 2023 14:22 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate Announces Closing of $4.0 Million Public Offering
13. September 2023 16:15 ET
|
Cingulate Inc.
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD
08. Juni 2023 07:00 ET
|
Cingulate Inc.
Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023 Pivotal Phase 3 Trials in Pediatric/Adolescent Patients on Schedule for 3Q 2023 Initiation KANSAS CITY, Kan., June ...